Evolution of the market of calcium dihydropyridinic antagonists and their use in the treatment of chronic forms of ischemic heart disease

Modern calcium antagonists of the dihydropyridine series are indicated as treatment of stable angina of different functional classes to be used singly (monotherapy) or combined with other antiischemic drugs. The best option is to combine the above antagonists with beta-blockers. There are some restr...

Full description

Saved in:
Bibliographic Details
Published inLikars'ka sprava no. 5-6; pp. 16 - 20
Main Authors Strashnyĭ, V V, Lysenko, A F
Format Journal Article
LanguageUkrainian
Published Ukraine 01.07.2002
Subjects
Calcium Channel Blockers - economics
Calcium Channel Blockers - therapeutic use
Dihydropyridines - economics
Dihydropyridines - therapeutic use
Humans
Marketing
Myocardial Ischemia - drug therapy
Online AccessGet full text

Cover

More Information
Summary:Modern calcium antagonists of the dihydropyridine series are indicated as treatment of stable angina of different functional classes to be used singly (monotherapy) or combined with other antiischemic drugs. The best option is to combine the above antagonists with beta-blockers. There are some restrictions in respect of only short-term-acting forms of nifedipine. Potential antiatherosclerotic properties of dihydropyridines have been shown in the experiment--these will, we believe, be corroborated in clinical settings.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ISSN:1019-5297